| Literature DB >> 19654066 |
Patricia L Earl1, Catherine Cotter, Bernard Moss, Thomas VanCott, Jeffrey Currier, Leigh Anne Eller, Francine McCutchan, Deborah L Birx, Nelson L Michael, Mary A Marovich, Merlin Robb, Josephine H Cox.
Abstract
Recombinant modified vaccinia virus Ankara (rMVA) expressing HIV-1 genes are promising vaccine candidates. Toward the goal of conducting clinical trials with one or a cocktail of recombinant viruses, four rMVAs expressing env and gag-pol genes from primary HIV-1 isolates representing predominant subtypes from Kenya, Tanzania, Uganda, and Thailand (A, C, D, and CRF01_AE, respectively) were constructed. Efficient expression, processing, and function of Env and Gag were demonstrated. All inserted genes were shown to be genetically stable after repeated passage in cell culture. Strong HIV-specific cellular and humoral immune responses were elicited in mice immunized with each individual vaccine candidate. The MVA/CMDR vaccine candidate expressing CRF01_AE genes has elicited HIV-specific T-cell responses in two independent Phase I clinical trials. Further testing of the other rMVA is warranted.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19654066 PMCID： PMC2743792 DOI： 10.1016/j.vaccine.2009.07.039
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641